{
    "symbol": "MDWD",
    "quarter": 2,
    "year": 2022,
    "date": "2022-08-10 00:31:03",
    "content": " Our market research, which was conducted by a third party, suggests that based on those results, it is anticipated that EscharEx will draw market share from all other debridement modalities, not just from the enzymatic and the autolytic debridement, but also from sharp debridement which is currently considered the most effective standard of care and comprise approximately 50% of this market. MediWound utilized $6.4 million in the second quarter of 2022 for its operational activities, which was affected by $1.8 million delay in collection from customers subsequently received in July $0.6 million shift in revenue for the third quarter due to the temporary shortage in supply chain. Our anticipated milestones include meeting with the FDA in the second half of this year regarding the EscharEx Phase 3 study, a PDUFA date of January 1, 2023 with the potential U.S. approval of NexoBrid, and MW005 Phase 1/2 clinical results for basal cell carcinoma in the second half of 2022. Your line is open. Your line is open. Your line is open. Your line is open."
}